Yvonne Remane

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

Wolfram Pönisch, Barbara Moll, Malvina Bourgeois et al. · Journal of Cancer Research and Clinical Oncology · 2013 · 38 citations · Full text

Hematological Malignancy, Oncology, Medicine +6

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

Wolfram Pönisch, Bruno Holzvogt, Madlen Plötze et al. · Journal of Cancer Research and Clinical Oncology · 2014 · 29 citations · Full text

Hematological Malignancy, Oncology, Hematology +5

Purity determination of amphotericin B, colistin sulfate and tobramycin sulfate in a hydrophilic suspension by HPLC

Corina Pfeifer, Georg M. Fassauer, Hagen Gerecke et al. · Journal of Chromatography B · 2015 · 26 citations

Pharmaceutical Science, Biotransformation, Medicine +12

Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial

Jan Christoph Koch, Andreas Leha, Helen Bidner et al. · The Lancet Neurology · 2024 · 21 citations · Full text

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neurological Disease +6

Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)

Andreas Wolff, Helen Bidner, Yvonne Remane et al. · Frontiers in Aging Neuroscience · 2024 · 17 citations · Full text